^
Association details:
| Biomarker: | MERTK expression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | RGX-019 (MERTK-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RGX-019-MMAE, a novel MERTK-targeting antibody-drug conjugate (ADC) with robust anti-tumor efficacy in both solid and liquid tumors.
Published date:
05/25/2023
Excerpt:
RGX-019-MMAE induced cytotoxicity in MERTK-expressing cancer cells and in xenografts, RGX-019-MMAE demonstrated anti-tumor efficacy including complete tumor regressions in various solid cancers such as TNBC as well as AML and MM. Anti-tumor efficacy was associated with increased overall survival...Collectively, RGX-019-MMAE’s robust anti-tumor efficacy in multiple aggressive tumors, and MERTK’s expression profile on cancer cells and normal tissue support further advancement of RGX-019-MMAE as a drug candidate for development in solid and liquid cancers.
DOI:
10.1200/JCO.2023.41.16_suppl.e15103
